Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-524-625"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-524-625"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-524-6872
lpv:speaker	lp:Silvia-Adriana Țicău2
lpv:spokenAs	unknown; Partidul Social Democrat (2009-07-14--2014-06-30)3 member; Delegation for relations with India (2009-09-16--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the Mercosur countries (2009-09-16--2014-06-30)3 substitute; ITRE (2012-01-19--2014-06-30)3 vice-chair; TRAN (2012-01-23--2014-06-30)3
lpv:translated text	". I voted for the report on the mobilisation of the European Globalisation Adjustment Fund (EGF) in response to Sweden’s application in respect of AstraZeneca. The application requests assistance for 543 redundancies at AstraZeneca from June to October 2011. A further 444 (987 in total) took place before and after the reference period and were part of the same collective redundancies programme. In the light of the fact that Sweden had a strong position in medical research, the collective redundancies in AstraZeneca had not been expected, despite the worsening situation in the pharmaceutical sector due to the rising dominance of generics and the outsourcing of research and development activities to no-EU countries. I believe that EGF funds should be allocated primarily to training and job search assistance. The package includes a job search allowance of EUR 7 170 (calculated for an average six-month period) and a mobility allowance of EUR 500. Access to EGF funding will help the workers who were made redundant to reintegrate in the labour market."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph